OmniAb Inc. discovery platform provides pharmaceutical industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. OmniAb Inc., formerly known as Avista Public Acquisition Corp. II, is based in SAN DIEGO.
| Revenue (Most Recent Fiscal Year) | $26.39M |
| Net Income (Most Recent Fiscal Year) | $-62.03M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.71 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.56 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -254.78% |
| Net Margin (Trailing 12 Months) | -229.11% |
| Return on Equity (Trailing 12 Months) | -21.37% |
| Return on Assets (Trailing 12 Months) | -18.84% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.70 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.70 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.24 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.17 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.61 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.58 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 122.14M |
| Free Float | 111.63M |
| Market Capitalization | $152.67M |
| Average Volume (Last 20 Days) | 0.75M |
| Beta (Past 60 Months) | 0.10 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 72.08% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |